SoftOx Solutions AS: Private Placement Resolved

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Softox Solutions AS ("SoftOx") has today resolved to carry out a Private Placement and a related debt conversion and resolved to issue a total of 58 158 206 new shares at a subscription price of NOK 0,105 per share.

The Private Placement and debt conversion have been resolved pursuant to the board authorization granted by the General Meeting held on 27 June 2025 and registered with the Norwegian Register of Business Enterprises on 12 August 2025.

Norwegian and international investors participated in the Private Placement. The Private Placement will generate NOK 5 750 000 in gross proceeds before transaction costs. The subscription price was determined based on market conditions through an agreed five-day VWAP mechanism.

In addition, the Board of Directors has resolved to increase the share capital through the conversion of outstanding bonus obligations owed to key employees. The debt conversion has been completed on the same subscription terms and at the same subscription price as the Private Placement.

Following the Private Placement and the debt conversion, the new share capital of the Company will be NOK 53 199 114.46 divided into 2 659 955 723 shares, each with a par value of NOK 0.02.

Deviation from shareholders' preferential rights The board of directors has considered the private placement in light of the equal treatment principles under the Norwegian Securities Trading Act and Oslo Børs' Oslo Rule Book II – Membership and Trading Rules and Oslo Børs' Circular no. 2/2014, and is of the opinion that the waiver of the preferential rights inherent in the following private placement is considered necessary in the interest of time and successful completion in order to secure funding of SoftOx. Taking into consideration the time, costs, and expected terms of alternative methods of securing the necessary funding, the board of directors concluded that the completion of the private placements, including the waiver of the preferential rights inherent to the private placements, is in the common interest of the shareholders of SoftOx. Further, the board assessed whether a subsequent offering should be carried out. As the private placement is limited and considering the cost inherent in a subsequent offering, the board concluded that a subsequent offering shall not be carried out.

For further information, please contact: Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87 Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165 Mail: ir@soft-ox.com

About SoftOx Solutions AS: SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective therapy for the treatment of respiratory infections in the airways and lungs. The Company is listed on Euronext Growth Oslo.